Cannabis

Healio Psychiatry has compiled a list of its five most-viewed stories in July.

Approximately 18% of patients in a rheumatic disease registry used cannabis in 2019, up from 6.3% in 2014, with the highest prevalence occurring in states where its use is legal, according to data published in Arthritis Care & Research.

The perceived risks associated with regular cannabis use declined among older adults in the United States during a recent 5-year period, a trend analysis showed.

Many physicians are reluctant to prescribe medical cannabis amid its uncertain legal status and preliminary, sometimes contradictory, clinical data on its safety and benefits.

Healio Psychiatry has compiled a list of its five most-viewed stories in June.

Cannabis use in middle to late adolescence may alter neurodevelopment, according to study results published in JAMA Psychiatry.

Recent cannabis users were more likely to report inadequate sleep durations than individuals who did not recently use cannabis, according to researchers. The association appeared to be stronger in heavy cannabis users.

Cannabis, cannabis-derived products and synthetic cannabinoids may slightly decrease rheumatoid arthritis disease activity, according to a meta-analysis published in the Journal of Clinical Rheumatology.

Younger age at first cannabis use or prescription drug misuse was linked to faster development of substance use disorders, according to study results in a research letter published in JAMA Pediatrics.

In a longitudinal analysis of twins, those who used cannabis more often than their identical twin during adolescence had worse socioeconomic outcomes in early adulthood, according to researchers.